Physician profile
Jack Maxwell
NPI 1679585087
$2,119.93
in general payments reported to CMS, 2019-2025
22 companies · $75.47 in 2025
The $75.47 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $511 · 2021: $79.24 · 2022: $48.64 · 2023: $364 · 2024: $130 · 2025: $75.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $526.21 | 2019-2020 | |
| Amgen INC. | $402.01 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $366.55 | 2019-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $287.46 | 2019-2025 | Rybelsus, Ozempic |
| Jazz Pharmaceuticals INC. | $93.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.82 | 2019-2020 | |
| Amarin Pharma, INC. | $54.36 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $43.59 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.73 | 2022 | |
| Exact Sciences Corporation | $30.54 | 2023-2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $28.89 | 2019-2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $25.10 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $19.67 | 2019 | |
| Inspire Medical Systems, INC. | $18.95 | 2024 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2023 | Xifaxan |
| Lundbeck LLC | $16.02 | 2025 | Vyepti |
| Lilly USA, LLC | $15.82 | 2023 | Mounjaro |
| Pfizer INC. | $14.91 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.87 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $11.15 | 2020 | |
| Neuronetics, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.